Intermittent Exposure of Primitive Quiescent Chronic Myeloid Leukemia Cells to Granulocyte-Colony Stimulating Factor In vitro Promotes their Elimination by Imatinib …
Clinical cancer research, 2006•AACR
Purpose: Primitive quiescent chronic myeloid leukemia (CML) cells are biologically resistant
to imatinib mesylate, an inhibitor of the p210BCR-ABL kinase. The present study was
designed to investigate whether either continuous or intermittent exposure of these cells to
granulocyte-colony stimulating factor (G-CSF) in vitro can overcome this limitation to the
effectiveness of imatinib mesylate therapy. Experimental Design: CD34+ leukemic cells
were isolated from six newly diagnosed chronic phase CML patients and cultured for 12 …
to imatinib mesylate, an inhibitor of the p210BCR-ABL kinase. The present study was
designed to investigate whether either continuous or intermittent exposure of these cells to
granulocyte-colony stimulating factor (G-CSF) in vitro can overcome this limitation to the
effectiveness of imatinib mesylate therapy. Experimental Design: CD34+ leukemic cells
were isolated from six newly diagnosed chronic phase CML patients and cultured for 12 …
Abstract
Purpose: Primitive quiescent chronic myeloid leukemia (CML) cells are biologically resistant to imatinib mesylate, an inhibitor of the p210BCR-ABL kinase. The present study was designed to investigate whether either continuous or intermittent exposure of these cells to granulocyte-colony stimulating factor (G-CSF) in vitro can overcome this limitation to the effectiveness of imatinib mesylate therapy.
Experimental Design: CD34+ leukemic cells were isolated from six newly diagnosed chronic phase CML patients and cultured for 12 days in serum-free medium with or without G-CSF and/or imatinib mesylate present either continuously or intermittently (three cycles of G-CSF for 0, 1, or 4 days ± imatinib mesylate for 0, 3, or 4 days). Every 4 days, the number of residual undivided viable cells and the total number of viable cells present were measured.
Results: Intermittent but not continuous exposure to G-CSF significantly accelerated the disappearance in vitro of initially quiescent CD34+ CML cells. This resulted in 3- and 5-fold fewer of these cells remaining after 8 and 12 days, respectively, relative to continuous imatinib mesylate alone (P < 0.04). Cultures containing imatinib mesylate and intermittently added G-CSF also showed the greatest reduction in the total number of cells present after 12 days (5-fold more than imatinib mesylate alone).
Conclusion: Intermittent exposure to G-CSF can enhance the effect of imatinib mesylate on CML cells by specifically targeting the primitive quiescent leukemic elements. A protocol for treating chronic-phase CML patients with imatinib mesylate that incorporates intermittent G-CSF exposure may offer a novel strategy for obtaining improved responses in vivo.
AACR
